Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

Conditions

Cholangitis, Sclerosing

What is the purpose of this trial?

The purpose of this research study is to determine whether the combination of UDCA and ATRA taken for 3 months will improve laboratory tests of liver and bile duct inflammation in patients with Primary Sclerosing Cholangitis (PSC). Our hypothesis is that a combination of these medications will improve the liver inflammatory tests in these patients, specifically a reduction in alkaline phosphatase (AP) by at least 30%.



Participation Guidelines

Age:
18 Years - 80 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Mayo Clinic
Yale University
Dates:
October 2011
Last Updated:
June 2, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01456468